Biophoton (Popp / UPE)

Insufficient evidence / under studyEgradePlausibility · Substrate real (UPE is measurable); the therapeutic 'information field' is unprovenPhotonic / Light

Ultraweak photon emission (UPE) is real, measurable, and a genuine biomarker frontier; the therapeutic 'biophoton information field' interpretation is unproven. Substrate real, therapy under study.

Origin & lineage

Fritz Popp, 1970s onward.

Claimed mechanism

A coherent 'biophoton field' acts as an information-bearing regulatory system.

Plausibility

Substrate real (UPE is measurable); the therapeutic 'information field' is unproven.

Evidence — grade E

Therapy grade E; UPE-as-biomarker research (metabolic / cancer-cell discrimination) is real and frontier.

Cross-reference

Gurvitch / Kaznacheev (historical UV-mitogenetic claim) shares this real visible-range UPE substrate.

Market

Makers: 'Biophoton therapy' device vendors (overlaps GDV).
Models: Biophoton devices.
Price: Varies (not verified).

Kernel — keep vs set aside

Keep — real substrate

UPE as a metabolic biomarker / cancer-cell discrimination — real frontier science.

Set aside — claim

Therapeutic 'biophoton medicine' is unproven.

Regulatory status by jurisdiction

Registration or clearance is a market-access fact, never proof of efficacy.

US — FDA	No therapeutic clearance.
EU — MDR	No therapeutic clearance.
Russia	No therapeutic clearance.
China — NMPA	No therapeutic clearance.
Australia — TGA	No therapeutic clearance.

Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC4561347/